An Open Label Study That Compares Varenicline to Transdermal Nicotine Patch for Smoking Cessation

PHASE3CompletedINTERVENTIONAL
Enrollment

730

Participants

Timeline

Start Date

January 31, 2005

Study Completion Date

June 30, 2006

Conditions
Smoking Cessation
Interventions
DRUG

varenicline (CP-526,555)

Trial Locations (22)

Unknown

Pfizer Investigational Site, Palo Alto

Pfizer Investigational Site, Santa Ana

Pfizer Investigational Site, Farmington

Pfizer Investigational Site, Lexington

Pfizer Investigational Site, Worcester

Pfizer Investigational Site, Portland

Pfizer Investigational Site, Brussels

Pfizer Investigational Site, Edegem

Pfizer Investigational Site, Ghent

Pfizer Investigational Site, Caen

Pfizer Investigational Site, Clermont-Ferrand

Pfizer Investigational Site, Limeil-Brévannes

Pfizer Investigational Site, Metz

Pfizer Investigational Site, Paris

Pfizer Investigational Site, Vandœuvre-lès-Nancy

Pfizer Investigational Site, Amsterdam

Pfizer Investigational Site, Enschede

Pfizer Investigational Site, Maastricht

Pfizer Investigational Site, Zutphen

Pfizer Investigational Site, London

Pfizer Investigational Site, London

Pfizer Investigational Site, Nottingham

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT00143325 - An Open Label Study That Compares Varenicline to Transdermal Nicotine Patch for Smoking Cessation | Biotech Hunter | Biotech Hunter